Polianta Ltd’s Acceleron Pharma XLRN Stock Holding History

Polianta Ltd’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,500	Closed	-$1M	–	107
2020 Q2	$1M	Buy	+10,500	New	+$1.01M	0.65%	42

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Polianta Ltd's XLRN Position: Q3 2020 in Review

Polianta Ltd sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 10,500 shares — an estimated $1M sold.

Polianta Ltd first reported a position in XLRN in Q2 2020 and held it in 1 quarter. The position peaked at $1M in Q2 2020. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Polianta Ltd reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Polianta Ltd sold 10,500 Acceleron Pharma shares in Q3 2020, an estimated $1M.
Polianta Ltd first reported a position in Acceleron Pharma in Q2 2020 and held it in 1 quarter.
Polianta Ltd's Acceleron Pharma position peaked at $1M in Q2 2020.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Polianta Ltd's 13F filing for Q3 2020, filed 7 Oct 2020.